Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Stellar Biotechnologies Inc. (SBOTF) and Amaran Biotechnology Inc. Continue Successful Collaboration

Stellar Biotechnologies and Amaran Biotechnology are happy to announce that their continuing alliance has proved successful in their primary objective to meet GMP-grade specifications of Stellar KLH for OBI-822 immunotherapy. KLH (Keyhole Limpet Hemocyanin) is a protein that stimulates the immune system while OBI-822 is the immunotherapy that uses this protein to combat immune disorders, cancer, and inflammatory responses.

The two companies collaborated in 2013 to manufacture OBI-822 so that it uses the Stellar KLH protein. Next, the companies hope to create large scale optimization processes to commercial manufacturing levels for widespread use. Amaran even commissioned a new biological production and research center in Taiwan’s Hsinchu Biomedical Science Park in Hsinchu County, Taiwan in preparation for immunotherapy expansion.

Stellar Biotechnologies is a world leader in KLH production while boasting a manufacturing facility that is the first of its kind. Amaran Biotechnology is a biopharmaceutical manufacturer that designs, develops, and produces pharmaceuticals in Taiwan.

Catherine Brisson, Chief Operating Office for Stellar Biotechnologies Inc., stated that,”Stellar’s collaboration with Amaran is an exciting clinical project. She continued that, “Through close cooperation with the Amaran team, we achieved each primary objective on-time and to the particular specifications required. We look forward to the scale-up stage with Amaran and to providing our partners with GMP Stellar KLH™ for their immunotherapy programs.”

Similarly, Tessie Che, General Manager and Chair of Amaran’s Board of Directors, stated, “We are very pleased with the success of our alliance with Stellar Biotechnologies, and the progress made towards commercial scale production of KLH for OBI-822.All of the programs that support OBI-822 and that will move this important immunotherapy closer to market launch are on track.”

Thanks to their continued collaboration, Stellar and Amaran have met the guidelines and specifications for the OBI-822 production alongside with the development and formulation of the Stellar KLH protein. When the protein is used with the immunotherapy, it can act as an immune stimulant, carrier molecule, or therapeutic vaccine conjugation. The companies anticipate the continued growth of their joint endeavor.

For more information, visit http://stellarbiotechnologies.com

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.